论文部分内容阅读
目的探讨中期因子(MK)和微血管密度(MVD)在骨肉瘤中的表达及其与肿瘤生物学行为的关系。方法采用免疫组织化学方法检测45例骨肉瘤标本MK和MVD的表达水平,并分析其与骨肉瘤恶性程度及预后的相关性。结果骨肉瘤中MK表达的阳性率为37.78%。MK和MVD的表达在骨肉瘤Price病理分级中差异无显著性(P>0.05),在Enneching外科分期中差异有显著性(P<0.01);肺转移组与无肺转移组MK和MVD的表达差异有显著性(P<0.01);骨肉瘤中MK与MVD表达差异有显著性(P<0.01)。结论MK和MVD与骨肉瘤的恶性程度密切相关,可作为判断肿瘤恶性程度及评价预后的指标。
Objective To investigate the expression of midkine (MK) and microvessel density (MVD) in osteosarcoma and its relationship with the biological behavior of tumor. Methods Immunohistochemical method was used to detect the expression of MK and MVD in 45 cases of osteosarcoma, and its correlation with malignant degree and prognosis of osteosarcoma was analyzed. Results The positive rate of MK expression in osteosarcoma was 37.78%. There was no significant difference in the expression of MK and MVD in the Price pathological grade of osteosarcoma (P> 0.05), but there was significant difference in Enneching surgical stage (P <0.01). The expression of MK and MVD in lung metastases and non-lung metastases The difference was significant (P <0.01). The expression of MK and MVD in osteosarcoma had significant difference (P <0.01). Conclusion MK and MVD are closely related to the malignant degree of osteosarcoma and can be used as an index to judge the degree of malignancy and evaluate the prognosis.